FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to pharmaceutics, particularly to drug delivery systems, and discloses a foaming composition and a method of treating an infection. Foaming composition is characterized by that it contains hydrogen peroxide, monoglyceride crystals, at least one acid and/or buffer, which are present in an amount required to provide pH from 3 to 5 in the body cavity, a blowing agent in an amount sufficient to blow the foaming composition and formation of foam, and water. Foaming composition is suitable for application in the body cavity during blowing with formation of foam, the foam is destroyed at body temperature with releasing hydrogen peroxide in the body tissue at pH from 3 to 5 and represents a carrier in the form of a foaming composition for the active agent delivery.
EFFECT: foaming composition is a delivery system capable of treating the entire body cavity surface due to its solid crystalline structure and can be used to treat an infection in the body cavity.
26 cl, 3 dwg, 19 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
FOAMING COMPOSITIONS FOR DELIVERY OF ACTIVE AGENT TO BODY CAVITY | 2018 |
|
RU2773520C2 |
HYDROGEL COMPOSITIONS WITH ERODIBLE SUBSTRATE | 2004 |
|
RU2384326C2 |
LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR VAGINAL DELIVERY | 2017 |
|
RU2753864C2 |
METHOD OF PREVENTING SEXUALLY TRANSMITTED VIRAL DISEASES, MEDICATION, METHOD OF OBTAINING MEDICATION, PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION AND CONDOM | 2010 |
|
RU2560879C2 |
SHORT ANTIMICROBIAL LIPOPEPTIDES | 2013 |
|
RU2627648C2 |
SEMI-SOLID COMPOSITIONS AND PHARMACEUTICAL PRODUCTS | 2010 |
|
RU2526803C2 |
TOSYLATE SALT OF THERAPEUTIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | 2008 |
|
RU2430099C2 |
TWO-PART OXIDISING SYSTEM FOR ORAL CARE COMPOSITIONS | 2013 |
|
RU2670989C2 |
ORAL CARE COMPOSITIONS | 2011 |
|
RU2604667C2 |
ZINC-AMINO ACID-HALIDE COMPLEX WITH CYSTEINE | 2013 |
|
RU2634261C2 |
Authors
Dates
2019-12-24—Published
2015-09-25—Filed